Exicure is developing nucleic acid therapies that target ribonucleic acid targets linked to neurological disorders and hair loss. To develop next-generation nucleic acid therapeutics Exicure is using their proprietary spherical nucleic acid (SNATM) platform. SNAs have a unique chemical structure with synthetic nucleic acid sequences densely radiating from a spherical core. This structure offers advantages over other nucleic acid technologies including unparalleled transfection efficiency into numerous cell and tissue types and multi-targeting capabilities. Exicure’s refined discovery and development process has led them to identify several promising candidates in CNS conditions quickly.

Exicure

Short description:

Drug notes:

Long description:

Jobs: